Here we speculated that the gain or loss of enhancer-promoter interactions and their corresponding DEGs such as up-regulated JRKL and down-regulate FA2H may constitute potential diagnostic or therapeutic targets for reversing doxorubicin resistance in breast cancer. This evidence concerns the gene JRKL and breast carcinoma.